Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Conversion of ABO blood groups.

J Goldstein1

  • 1New York Blood Center, New York 10021.

Transfusion Medicine Reviews
|July 1, 1989
PubMed
Summary
This summary is machine-generated.

Researchers are converting A and B red blood cells into universal O type by removing specific sugars. Treated group B cells show normal lifespan in humans, but group A cells require further modification for complete antigen removal.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection of abnormal proliferation in histologically 'normal' colonic biopsies using FTIR-microspectroscopy.

Scandinavian journal of gastroenterology·2004
Same author

Fourier transform infrared microspectroscopy as a quantitative diagnostic tool for assignment of premalignancy grading in cervical neoplasia.

Journal of biomedical optics·2004
Same author

Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine.

Neurology·2004
Same author

Search for Kaluza-Klein graviton emission in pp collisions at square root[s] = 1.8 TeV using the missing energy signature.

Physical review letters·2004
Same author

Search for pair production of scalar top quarks in R-parity violating decay modes in pp collisions at square root of s=1.8 TeV.

Physical review letters·2004
Same author

Measurement of prompt charm meson production cross sections in pp collisions at square root s = 1.96 TeV.

Physical review letters·2003
Same journal

Assessment of CTLA-4, LAG-3, and TIM-3 Expression in Pediatric Patients With β-Thalassemia Major and Their Association With Alloimmunization.

Transfusion medicine reviews·2026
Same journal

A Reply to "Beyond Implementation: The Need for Validation, Equity, and Real-World Accountability in AI for Transfusion Medicine".

Transfusion medicine reviews·2026
Same journal

Beyond Implementation: The Need for Validation, Equity, and Real-World Accountability in AI for Transfusion Medicine.

Transfusion medicine reviews·2026
Same journal

Trust Over Knowledge: Rethinking Donor Iron Supplementation Strategies in Modern Blood Services-Authors' reply.

Transfusion medicine reviews·2026
Same journal

The Effect of Stress Ball and Music on Anxiety, Distress, and Pain Levels During Platelet Apheresis Donation: Randomized Controlled Trial.

Transfusion medicine reviews·2026
Same journal

Therapeutic Plateletpheresis for Thrombocytosis: Critical Analytic Reviews and Original Multicenter Experience.

Transfusion medicine reviews·2026
See all related articles

Area of Science:

  • Biochemistry
  • Immunology
  • Transfusion Medicine

Background:

  • Blood group A and B antigens are carbohydrate-based, with distinct terminal sugars.
  • The H antigen, found on group O cells, can be revealed by removing these terminal sugars.
  • Maintaining red blood cell viability during antigen removal is crucial for transfusion applications.

Purpose of the Study:

  • To develop methods for converting group A and B erythrocytes to a universal O type.
  • To assess the in vivo viability and immunogenicity of treated erythrocytes in preclinical models and human volunteers.

Main Methods:

  • Utilizing specific exoglycosidases to remove terminal sugars from A and B antigens on erythrocytes.
  • Developing conditions to ensure metabolic and membrane integrity of red blood cells post-treatment.

Related Experiment Videos

  • Conducting autologous transfusions in gibbons and preclinical studies in human volunteers.

    • Main Results:

    • Treated group B erythrocytes demonstrated normal in vivo lifespans in both group A and O recipients.
    • Group A and O recipients of treated group B cells showed a temporary increase in anti-B antibody titers.
    • Exoglycosidase treatment of group A erythrocytes did not fully remove all detectable A antigens due to internal antigenic sites.

    Conclusions:

    • Enzymatic modification of erythrocytes shows promise for creating universal donor cells.
    • Further strategies, including combined enzymatic treatments, are needed to fully convert group A cells to the O type.
    • The long-term implications of transient antibody titer increases require further investigation.